ScoreWhy is Kringle Pharma, Inc. ?
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -708.28
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -708.28
2
Poor long term growth as Operating profit has grown by an annual rate -241.75% of over the last 5 years
3
With a growth in Net Sales of 1498.4%, the company declared Very Positive results in Jun 26
- DEBT-EQUITY RATIO (HY) Lowest at -135.4 %
- RAW MATERIAL COST(Y) Fallen by -7,549% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 7.32 times
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 5.14%, its profits have fallen by -1.8%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 5.14% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 43.58%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Kringle Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kringle Pharma, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Kringle Pharma, Inc.
6.51%
-0.68
56.01%
Japan Nikkei 225
43.58%
1.48
29.43%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-32.57%
EBIT Growth (5y)
-241.75%
EBIT to Interest (avg)
-749.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.05
Tax Ratio
0.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.66
EV to EBIT
-1.02
EV to EBITDA
-1.02
EV to Capital Employed
-1.46
EV to Sales
12.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-96.91%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -135.4 %
RAW MATERIAL COST(Y)
Fallen by -7,549% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 7.32 times
NET SALES(Q)
Highest at JPY 287.15 MM
OPERATING PROFIT(Q)
Highest at JPY -118.67 MM
OPERATING PROFIT MARGIN(Q)
Highest at -41.33 %
PRE-TAX PROFIT(Q)
Highest at JPY -114.7 MM
NET PROFIT(Q)
Highest at JPY -115.08 MM
EPS(Q)
Highest at JPY -13.73
-3What is not working for the Company
ROCE(HY)
Lowest at -61.23%
CASH AND EQV(HY)
Lowest at JPY 3,283.81 MM
Here's what is working for Kringle Pharma, Inc.
Net Sales
At JPY 287.15 MM has Grown at 1,498.4%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (JPY MM)
Debt-Equity Ratio
Lowest at -135.4 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at JPY 287.15 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY -118.67 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at -41.33 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY -114.7 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY -115.08 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY -13.73
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Debtors Turnover Ratio
Highest at 7.32 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -7,549% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Kringle Pharma, Inc.
Cash and Eqv
Lowest at JPY 3,283.81 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Footer loading
